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Abstract
Background:  CXCR2 chemokine ligands CXCL1, CXCL5 and CXCL6 were shown to be
involved in chemoattraction, inflammatory responses, tumor growth and angiogenesis. Here, we
comparatively analyzed their expression profile in resection specimens from patients with
colorectal adenoma (CRA) (n = 30) as well as colorectal carcinoma (CRC) (n = 48) and
corresponding colorectal liver metastases (CRLM) (n = 16).
Methods: Chemokine expression was assessed by microdissection, quantitative real-time PCR
(Q-RT-PCR), the enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC).
Results:  In contrast to CXCL6, we demonstrated CXCL1 and CXCL5 mRNA and protein
expression to be significantly up-regulated in CRC and CRLM tissue specimens in relation to their
matched tumor neighbor tissues. Moreover, both chemokine ligands were demonstrated to be
significantly higher expressed in CRC tissues than in CRA tissues thus indicating a progressive
increase in the transition from the premalignant condition to the development of the malignant
status. Although a comparative analysis of the CXCL1/CXCL5 protein expression profiles in CRC
patients revealed that the absolute expression level of CXCL1 was significantly higher in
comparison to CXCL5, mRNA- and protein overexpression of CXCL5 in CRC and CRLM tissues
was much more pronounced (80- and 60- fold in CRC tissues, respectively) in comparison to
CXCL1 (5- and 3.5- fold in CRC tissues, respectively).
Conclusion: Our results demonstrate a significant association between CXCL1 and CXCL5
expression with CRC and CRLM suggesting for both chemokine ligands a potential role in the
progression from CRA to CRC and thus, in the initiation of CRC.
Background
To date, colorectal cancer (CRC) constitutes one of the
leading causes of cancer-related deaths worldwide. In
spite of many currently available and continuously
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improving therapies for early stage colon cancer, the
majority of CRC patients develop metastases which
worsen the prognosis for survival dramatically [1,2].
The development of cancer metastases is a complex proc-
ess consisting of various interacting mechanisms, which
involve numerous biochemical and immunological
changes like abnormally expressed growth factors and
cytokines [3]. One group of cytokines that recently
attracted a lot of attention with view to cancer-related
mechanisms, are small signaling molecules termed chem-
okines [4]. Chemokines were originally identified in
inflammatory pathways stimulating the migration of leu-
cocytes, such as neutrophils and natural killer cells [5,6].
Only in recent years chemokines were reported to induce
the migration of tumor cells and their expression was cor-
related with tumor growth, angiogenesis and metastatic
potential in various human carcinomas and animal mod-
els [7-9].
In the present study, we monitored the expression profiles
of several ELR+ CXC chemokines and their corresponding
receptor CXCR2 in benign and malign colorectal condi-
tions and in CRLM. We focused on CXCL1 [growth-
related oncogene α (GROα)] [10], CXCL5 [epithelial neu-
trophil -activating protein 78 (ENA-78)] [11] and CXCL6
[granulocyte chemotactic protein-2 (GCP2)] [12], all
structurally related members of the CXC chemokine fam-
ily. This chemokine family is further subdivided into ELR+
and ELR- CXC chemokines, based on the presence or
absence of the amino acid sequence Glu-Leu-Arg (ELR)
preceding the first conserved cysteine amino acid residue
in the primary structure of the CXC chemokines. All three
chemokines under investigation contain the ELR motif,
which is important for ligand/receptor interactions and
the regulation of CXC chemokine induced angiogenesis
[13-15].
The angiogenic activity of all ELR+ CXC chemokines is
mediated by the G-protein-coupled receptor CXCR2 [16],
although some ELR+ CXC chemokines also signal through
CXCR1. While CXCL1 activates and interacts exclusively
by CXCR2, CXCL5 and CXCL6 signal through both recep-
tors [17].
All three genes are structurally related to another member
of the ELR+ chemokines, CXCL8 [interleukin-8 (IL-8)],
which has recently been associated with CRC pathology
and various other tumor types [18-21]. Like CXCL8 and
other members of the ELR+  CXC chemokine family,
CXCL6 is a neutrophil chemoattractant that was recently
demonstrated to promote tumor growth through its ang-
iogenic effects in human tumors and animal models
[22,23].
Involvement of CXCL5 has also been reported in different
neoplastic processes with major focus on non small cell
lung cancer (NSCLC), where CXCL5 was shown to be an
important angiogenic factor [24]. Accordingly, in pancre-
atic cancer cell lines angiogenic activity was demonstrated
[25] and with view to CRC elevated protein quantities
have been reported [26].
The third ELR+ chemokine under investigation, CXCL1,
originally identified as melanoma growth stimulating
activity, has recently been adressed a role in HIV-infection
[27] and correlated with tumorigenic and angiogenic
effects and metastasis in squamous cell carcinoma and
melanoma [28,29]. Recently, prostaglandin E2  (PGE2)
was shown to induce the expression of CXCL1 in human
CRC cells and to induce microvascular endothelial cell
migration and tube formation in vitro [30]. Moreover, ele-
vated CXCL1 expression has recently been associated with
an invasive phenotype in human colon carcinoma cells
[31] and down-regulation of the matrix protein fibulin-1
[32].
Despite the increasing number of studies indicating a role
for CXCL1, CXCL5 and CXCL6 in different cancer types
and processes, their relevance with view to the develop-
ment of CRC is still rather limited. Thus, we were
prompted to investigate their expression profiles in color-
ectal adenoma (CRA) specimens as premalignant stages in
the development of CRC, further in CRC tissues of differ-
ent tumor categories and corresponding colorectal liver
metastases (CRLM), to track potential differences in the
expression levels between the transition from a premalig-
nant condition to a colorectal malignancy.
Methods
Patients
Surgical specimens and corresponding normal tissue from
the same samples were collected from patients with CRA
(n = 30), CRC of different tumor categories (n = 48) and
synchronous or metachronous CRLM (n = 16) who
underwent surgical resection at our department between
January 2003 and october 2006. Informed consent for tis-
sue procurement was obtained from all patients. The
study was approved by the ethics commission of the Ärzt-
ekammer of the Saarland, Germany. The clinical variables
presented in Table 1 and 2 were obtained from the clinical
and pathological records and are in accordance with the
UICC/TNM classification [33].
Tissue preparation
Tissue samples were collected immediately after resection,
snap frozen in liquid nitrogen and then stored at -80°C
until they were processed under nucleic acid sterile condi-
tions for RNA and protein extraction. Tumor samples
were taken from vital areas of histopathologically con-BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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firmed (R.M.B. and M.W.) adenocarcinomas and liver
metastases, respectively. As corresponding normal tissue
we used adjacent unaffected mucosa, 2–3 cm distal to the
resection margin from the same resected adenocarcinoma
or liver specimen, respectively. All tissues obtained were
reviewed by a minimum of two experienced pathologists
(M.W. et al.) and examined for the presence of tumor cells.
As minimum criteria for usefulness for our studies we only
chose tumor tissues in which tumor cells occupied a
major component (> 80%) of the tumor sample.
Single-strand cDNA synthesis
Total RNA was isolated using RNeasy columns from Qia-
gen (Qiagen, Hilden, Germany) according to the manu-
facturer's instructions. RNA integrity was confirmed
spectrophotometrically and by electrophoresis on 1%
agarose gels. For cDNA synthesis 5 μg of each patient total
RNA sample were reverse-transcribed in a final reaction
volume of 50 μl containing 1× TaqMan RT buffer, 2.5 μM/
l random hexamers, 500 μM/l each dNTP, 5.5 mM/l
MgCl2, 0.4 U/μl RNase inhibitor, and 1.25 U/μl Multi-
scribe RT. All RT-PCR reagents were purchased from
Applied Biosystems (Applied Biosystems, Foster City,
CA). The reaction conditions were 10 min at 25°C, 30
min at 48°C, and 5 min at 95°C.
Real-time PCR
Expression profiles of CXCL1, CXCL5 and CXCL6 were
monitored in CRA and CRC tissue specimens and corre-
sponding CRLM by Q-RT-PCR. Adjacent, disease and
tumor free colorectal epithelium and liver samples served
as control groups, respectively. All Q-RT PCR assays con-
taining the primer and probe mix were purchased from
Applied Biosystems and utilized according to the manu-
facturer's instructions. PCR reactions were carried out
using 10 μl 2× Taqman PCR Universal Master Mix No
AmpErase® UNG (Applied Biosystems) and 1 μL gene
assay, 8 μL RNase-free water and 1 μl cDNA template (50
mg/l). The theoretical basis of the Q-RT assays is described
in detail elsewhere [34]. All reactions were carried out in
duplicate along with no template controls and an addi-
tional reaction in which reverse transcriptase was omitted
to assure absence of genomic DNA contamination in each
RNA sample. For signal detection, the ABI Prism 7900
sequence detector (Applied Biosystems), was pro-
grammed to an initial step of 10 min at 95°C, followed by
40 thermal cycles of 15 s at 95°C and 10 min at 60°C and
the log-linear phase of amplification was monitored to
obtain CT values for each RNA sample.
Gene expression of all target genes was analyzed in rela-
tion to the levels of the slope matched housekeeping
genes phosphomannomutase (PMM1) and cyclophilin C
(CycC) [35]. Since reporting of data obtained from raw CT
values falsely represent the variations, we converted the
individual CT values to the linear form as follows:
Consequently, the normal tissue becomes the 1 × sample,
and all other quantities are expressed as an n-fold differ-
ence relative to this tissue.
Isolation of total protein
Protein lysates from frozen tissues were extracted with a
radioimmunoprecipitation (RIPA) cell lysis and extrac-
tion buffer (Pierce, Rockford, USA). Total protein content
was assessed by using the Pierce BCA protein assay reagent
kit (Pierce).
Fold difference
mean C  pathological tissue mean C  cal TT =
−− 2
(i ibrator delta CT ) =
− 2
Table 1: Clinical characteristics of patients with colorectal 
carcinomas and colorectal liver metastases
Factor CRC2 n = 48 CRLM3 n = 164
Localization of primary tumor
Colon 22 6
Rectum 26 8
Gender
Male 29 7
Female 19 7
Age, yr5 63.7 (47–78) 60,3 (41–76)
Largest tumor diameter (cm)5 4.6 (1.2–9.1) 4,2 (1.5–5.5)
TNM1 category of primary tumor
I8 1
II 15 2
III 15 10
IV 10 1
Grading
I0 0
II 21 4
III 27 10
Chemotherapy before operation 0 2
Radiotherapy before operation 0 2
1Tumor-node-metastasis; 2Colorectal carcinoma; 3Colorectal liver 
metastases; 416 CRLM originating from 14 CRC patients; 5Median 
with range in parentheses.
Table 2: Clinical characteristics of patients with colorectal 
adenomas
Factor CRA1 n = 30
Localization of colorectal adenoma, respectively
Colon 23
Rectum 7
Gender
Male 17
Female 13
Age, yr2 65.7 (42–75)
1Colorectal adenoma; 2Median with range in parentheses.BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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Enzyme-linked immunosorbant assay (ELISA)
Tissue concentrations of CXCL1, CXCL5 and CXCL6 in
the lysates were determined by sandwich-type ELISA
according to the manufacturer's protocol: R&D systems
(DuoSet, R&D Systems Inc. Minneapolis, Minnesota,
USA). The absorbance was read at 450 nm.
Immunohistochemistry
Operative specimens were routinely fixed in formalin and
subsequently embedded in paraffin. Before staining, 4-
μm thick paraffin-embedded tissue sections were
mounted on Superfrost Plus slides, deparaffinized and
rehydrated in graded ethanol to deionized water. The sec-
tions were microwaved with an antigen retrieval solution
(Target Retrieval, Dakocytomation, Carpinteria, CA, USA)
and after blocking of endogenous peroxidase activity with
3% hydrogen peroxide, the sections were further blocked
for 30 minutes with normal rabbit serum. Overnight incu-
bation at 4°C with primary goat polyclonal anti-human
CXCL5 antibody (15 μg/ml, AF254, R&D Systems, Minne-
apolis, Minn., USA) or primary goat anti-human CXCL1
antibody (3.5 μg/ml, sc-1374, Santa Cruz Biotechnology,
Santa Cruz, Calif., USA) was followed by incubation of
secondary biotinylated biotinylated rabbit anti-goat IgG
antibody and the avidin-biotin-peroxidase reaction
(Vectastain ABC ELITE Kit, Vector Laboratories, Burlin-
game, CA, USA). After colour reaction with aminoethyl-
carbazol solution (Merck, Darmstadt, Germany), tissues
were counterstained with haematoxylin. Negative con-
trols were performed in all cases omitting primary anti-
body. All pictures were taken using a digital camera
(Olympus DP71, Olympus Optical Co, Ltd, Tokyo,
Japan).
Laser Capture Microdissection
Laser microbeam microdissection (LMM) was employed
for obtaining pure tumor cell and pure normal cell sam-
ples for subsequent genetic analysis. LMM was performed
on three samples for each tissue type for CXCL1, CXCL5
and CXCL6. Histochemical staining was used on cryo sec-
tions before microdissection. Specimen preparation,
microdissection and catapulting were performed follow-
ing a laser pressure catapulting protocol according to the
manufacturer's instructions (P.A.L.M. Microlaser Technol-
ogies, Bernried, Germany). RNA was extracted using the
P.A.L.M. RNA extraction kit and for reverse transcription
the invitrogen reverse transcription kit (Invitrogen Life
Technologies, Karlsruhe, Germany) was applied. Subse-
quently quantitative PCR analysis was performed.
Calculations and Statistical Methods
Expression profiles of CXCL1, CXCL5 and CXCL6 in the
different groups are shown as mean and standard error of
the mean (SEM). Statistical calculations were done with
the MedCalc software package (MedCalc software, Mari-
akerke, Belgium) [36]. Where appropriate, either the Stu-
dent's t-test or the Wilcoxon's rank sum test was applied
to test for group differences of continuous variables. A P
value of 0.05 or less was deemed significant. To measure
how variables are related we performed a bivariate corre-
lation analysis using the spearman ρ correlation coeffi-
cient.
Results
CXCL1, CXCL5 and CXCL6 mRNA expression
CXCL1 and CXCL5 mRNA expressions were significantly
up-regulated in all CRC tissue specimens in relation to the
matched tumor neighbor tissues (P < 0.001, respectively;
Fig. 1). In addition, CXCL1 also revealed significant up-
regulation in the CRA tissues (P < 0.05). In contrast, no
significant up-regulation of CXCL6 mRNA expression was
observed in either tissue type (Fig. 1). In CRA tissues also
CXCL5 showed no significant up-regulation, indicating
that CXCL5 is not overexpressed in preliminary stages of
CRC. However, CXCL5 overexpression in CRC tissues
revealed a much more pronounced 80-fold up-regulation
in comparison to CXCL1, which only showed a 5-fold
overexpression in CRC patients. Furthermore, we detected
a significant clinicopathological association between
CXCL5 expression and early tumor categories of CRC (P <
0.001), which did not occur for CXCL1 or CXCL6 (Fig. 2).
In metastatic samples, CXCL1 and CXCL5 expression was
also significantly elevated relative to corresponding nor-
mal liver tissues (P < 0.05, respectively, Fig. 3). Again,
CXCL5 expression was much more pronounced. Between
metastases and corresponding primary tumors we
observed no significant difference in mRNA expression
(Fig. 3). Notably, CXCL5 expression was significantly
lower in the corresponding primary tumors (n = 14) of the
CRLM presented in Fig. 3 compared to the entire CRC
patient cohort (n = 48), which comprised all tumor cate-
gories 1–4 as shown in Fig. 1. Showing that lower T- cate-
gories (T1–2) express almost 100-fold significantly more
CXCL5 than higher T-categories (T3–4) (Fig. 2B), led us to
review the T- categories of the corresponding primary
tumors of the CRLM. It turned out that 11 out of 14
tumors were classified as T3 and T4 tumors (Table 1), thus
explaining the results presented in Fig. 2B.
To verify that up-regulation of CXCL1 and CXCL5 is gen-
erated exclusively by tumor cells rather than inflamma-
tory cells or other non-malignant cells in the tissue blocks,
we routinely analysed Q-RT-PCR expressions of several
sections of microdissected tumor and normal cells from
three specimens of all tissue types under investigation.
Moreover, we generally determined the differences
between gene expressions from matched normal/cancer
samples constituting the basis for all our calculations.BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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CXCL1, CXCL5 and CXCL6 protein expression
CXCL1 and CXCL5 protein expressions, as assessed by
ELISA, showed a significant up-regulation in the CRC tis-
sue specimens in comparison to the unaffected corre-
sponding mucosa tissues, respectively (P  < 0.001) as
demonstrated in Figures 4A and 4B. In consistence with
the results obtained at the mRNA level, CXCL5 protein
overexpression was much more pronounced correspond-
ing to a 60-fold expression increase compared to only a
3.5-fold expression increase for CXCL1. Although signifi-
cant up-regulation of CXCL1 proteins was also detected in
CRA tissues, the level of CXCL1 protein expression in the
CRC tissues was significantly 3.5-fold higher than in the
CRA tissues (P < 0.05, Fig. 4A). Similarly, CXCL5 showed
significant protein up-regulation in the CRC patient tis-
sues with respect to the CRA tissues (Fig. 4B). Again, this
overexpression was much more pronounced in compari-
son to CXCL1, demonstrating a 20-fold up-regulation for
CXCL5 versus a 3.5-fold up-regulation for CXCL1, thus
indicating a prominent progressive protein expression
increase in the transition from the premalignant condi-
tion to the development of colorectal malignancies. In
contrast, CXCL6 protein expressions showed no signifi-
cant up-regulation in either tissue type (Fig. 4C).
Comparative analysis of the CXCL1/CXCL5 absolute pro-
tein quantities in CRC patients revealed a significantly
higher CXCL1 expression (P < 0.05) of almost 14000 pg/
ml compared to approximately 4000 pg/ml CXCL5 (Fig.
5A). On the other hand, we also observed a significantly
higher CXCL1 expression level in the CRA tissues, where
4000 pg/ml CXCL1 compared to 200 pg/ml CXCL5, indi-
cating that the basic expression level of CXCL1 is generally
higher in both disease entities in comparison to CXCL5
(Fig. 5B).
Cell-specific expression of CXCL1 and CXCL5 by IHC
Detection of CXCL1 and CXCL5 expression was assessed
by immunohistochemical staining in CRA, CRC and
CRLM specimens and corresponding normal tissues (Fig
6). Immunostaining with CXCL1 -specific antibodies
showed weak apical epithelial signals and weak staining
of goblet cells in the corresponding normal areas of CRA
and CRC tissues (Fig. 6A and 6C). Also in CRA tissues
CXCL1 revealed only apical weak to medium staining of
epithelial cells (Fig. 6B). In contrast, intense apical and
basal CXCL1 staining signals were found in epithelial cells
of CRC tissues and to a lesser extent also positive signals
were observed in mesenchymal cells of the CRC tissues
(Fig. 6D). In tumor neighbor tissues of CRLM we observed
medium CXCL1 staining intensities of fine granular tex-
ture in hepatocytes (Fig. 6E) while Glisson's triangles were
strictly negative (left upper corner of Fig. 6E). In contrast,
CRLM specimens displayed intense cytoplasmic CXCL1
staining signals in ubiquitous distribution (Fig 6F). Inter-
estingly, both colorectal tumor tissues and hepatic meta-
static tumor tissues showed apical and basal distribution
of CXCL1 signals, whereas CRA tissues and unaffected cor-
responding neighbor tissues of CRC and CRA displayed
only apical CXCL1 signals. Also for CXCL5 we detected
only very weak staining intensities in the unaffected corre-
sponding neighbor tissues of CRC and CRA restricted to
some insular cytoplasmic signals in basal crypt cells
(Fig.7A and 7C). Likewise, no substantial immunostain-
ing was detected within CRA tissue specimens for CXCL5
with the exception of very insular positive signals in mes-
enchymal or goblet cells (Fig. 7B). In contrast, we
observed intense CXCL5 staining within CRC specimens
mainly concentrated in epithelial cells and only randomly
interspersed positive signals in mesenchymal cells (Fig.
7D). These findings indicate that the high CXCL5 expres-
sion detected in our mRNA and protein analysis is attrib-
uted to positive signals of tumor cells rather than
infiltrating immune cells.
In tumor neighbor tissues of CRLM we detected no sub-
stantial CXCL5 reactivity. Only insular dotlike, cytoplas-
mic signals were randomly interspersed in some
hepatocytes (Fig. 7E). In contrast, we observed intensive
staining signals in epithelial and mesenchymal cells
Expression of CXCL1, CXCL5 and CXCL6 in colorectal ade- noma (CRA) and colorectal carcinoma (CRC) tissue speci- mens as determined by Q-RT-PCR Figure 1
Expression of CXCL1, CXCL5 and CXCL6 in color-
ectal adenoma (CRA) and colorectal carcinoma 
(CRC) tissue specimens as determined by Q-RT-
PCR. Q-RT-PCR data are expressed as mean +/- standard 
error of the mean (SEM), * P < 0.05, ** P < 0.001, n = 30 and 
48, respectively. Fold increase above 1 indicates chemokine 
overexpression in CRA and CRC tissues related to unaf-
fected neighbor tissues, respectively.BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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Expression of (A) CXCL1, (B) CXCL5 and (C) CXCL6 in different tumor categories of colorectal carcinoma (CRC) as deter- mined by Q-RT-PCR Figure 2
Expression of (A) CXCL1, (B) CXCL5 and (C) CXCL6 in different tumor categories of colorectal carcinoma 
(CRC) as determined by Q-RT-PCR. Q-RT-PCR data are expressed as mean +/- standard error of the mean (SEM), * P < 
0.05, ** P < 0.001, n = 23 and 25, respectively. Fold increase above 1 indicates chemokine overexpression in CRC tissues 
related to unaffected neighbor tissues, respectively. Note the different scale for CXCL1, CXCL5 and CXCL6 expression.BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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within tumor areas of CRLM specimens (Fig. 7F). Well
confined from the positive signals in the tumor areas we
also observed unspecific staining of bile pigments (left
upper image border in Fig. 7F).
Comparative CXCR2 expression in different colorectal 
conditions
While we observed no significant up- or down regulation
of CXCR2 mRNA expression in CRA and CRLM tissue
specimens, we found significant CXCR2 up-regulation in
CRC tissues (P < 0.05) (Fig. 8).
Discussion
This study provides evidence that significantly increased
CXCL1 and CXCL5 expression associates with the transi-
tion from a premalignant condition to colorectal malig-
nancies. In contrast, CXCL6 showed no association with
colorectal malignancies in our studies. CXCR2, the corre-
sponding receptor, respectively, showed also significant
up-regulation in CRC tissues and no significant up-regula-
tion in the CRA tissues thus matching the expression pro-
file of CXCL1 and CXCL5.
As we have shown previously (21) CXCL8 mRNA and pro-
tein expression is significantly up-regulated in CRC speci-
mens in relation to CRA and UC tissues. Moreover,
CXCL8 expression revealed a close correlation with tumor
grading. Most interestingly, CXCL8 up-regulation was
Expression of (A) CXCL1, (B) CXCL5 and (C) CXCL6 in  colorectal adenoma (CRA) and colorectal carcinoma (CRC)  tissue specimens as determined by ELISA assays Figure 4
Expression of (A) CXCL1, (B) CXCL5 and (C) 
CXCL6 in colorectal adenoma (CRA) and colorectal 
carcinoma (CRC) tissue specimens as determined by 
ELISA assays. Elisa results are presented as absolute values 
of pg per ml chemokine ligand per mg total protein in CRA 
and CRC tissues and unaffected neighbor tissues, respec-
tively. The data are expressed as mean +/- standard error of 
the mean (SEM), * P < 0.05, ** P < 0.001, n = 30 and 48, 
respectively. Note the different scale for CXCL1, CXCL5 
and CXCL6 expression.
Expression of CXCL1, CXCL5 and CXCL6 in colorectal liver  metastases (CRLM) and corresponding primary colorectal  tumors as determined by Q-RT-PCR Figure 3
Expression of CXCL1, CXCL5 and CXCL6 in color-
ectal liver metastases (CRLM) and corresponding 
primary colorectal tumors as determined by Q-RT-
PCR. Q-RT-PCR data are expressed as mean +/- standard 
error of the mean (SEM), * P < 0.05, ** P < 0.001, n = 16 and 
14, respectively. Fold increase above 1 indicates chemokine 
overexpression in affected tissues related to unaffected 
neighbor tissues, respectively.BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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most enhanced in synchronous and metachronous
CRLM, if compared with the corresponding primary CRC
tissues thus suggesting an association between CXCL8
expression, induction and progression of colorectal carci-
noma and the development of colorectal liver metastases.
Thus, we observed for the expression levels of CXCL8,
CXCL1 and CXCL5 a significant association with the
development of colorectal carcinoma and also CRLM. For
CXCL8 we also observed on the protein level that the
expression was significantly higher in tumor stage 4 in
comparison to the lower tumor stages. Also Q-RT-analysis
revealed a similar effect for CXCL8.
However, in recent years a number of studies have
emerged demonstrating CXCL6 involvement in tumor
development and angiogenesis in various animal models
and human tumors [22,23]. Thus, van Coillie et al pro-
vided evidence that mouse CXCL6 gene transfer enhanced
the development of Bowes melanoma tumors coupled
with a higher neutrophil influx and significantly increased
angiogenesis [22]. Moreover, CXCL6 production by
endothelial cells within gastrointestinal tumors was
shown to contribute to tumor development and neovas-
cularization [23] and constitutive CXCL6 secretion was
recently demonstrated in a panel of small cell lung cancer
(SCLC) cell lines and in clinical SCLC specimens [37].
Despite the increasing number of studies suggesting a can-
cer-related role for CXCL6, we observed no significant
CXCL6 up-regulation in CRC tissues or CRLM, neither on
the RNA nor on the protein level. Moreover, we measured
no significant difference in CXCL6 expression between
CRA, CRC or CRLM tissues in our patient cohort. In con-
trast, both other chemokines under investigation, CXCL1
and CXCL5, showed significant RNA and protein up-reg-
ulation in all colorectal malignancies comprising CRC
and CRLM tissues. Accordingly, our IHC results confirmed
that this up-regulation resulted from tumor cells as we
detected intense CXCL1 and CXCL5 staining signals in
CRC and CRLM specimens mainly concentrated in the
epithelial cells of these tissues.
These findings are supported by a number of recent stud-
ies adressing a cancer-related role to these chemokines.
Thus, elevated CXCL5 protein levels have been reported in
CRC patients [26] and in human pancreatic cancer cell
lines [25]. The mechanistic involvement of CXCL5 in the
promotion of NSCLC was recently investigated in a study
by Pöld et al [38], who demonstrated that enhanced
tumor growth of COX-2 over-expressing tumors in a
immunodeficient mouse model was associated with
enhanced CXCL5 expression and inhibited by neutraliz-
ing anti-CXCL5 sera.
Also CXCL1 has recently been shown to promote tumor
growth and angiogenesis in different tumor types. In
human CRC cells, Wang et al [30] demonstrated recently,
that PGE2 induced the expression of CXCL1 in the human
CRC cells and also microvascular endothelial cell migra-
Expression of CXCL1 and CXCL5 and in (A) colorectal carcinoma (CRC) and (B) colorectal adenoma (CRA) tissue specimens  as determined by ELISA assays Figure 5
Expression of CXCL1 and CXCL5 and in (A) colorectal carcinoma (CRC) and (B) colorectal adenoma (CRA) 
tissue specimens as determined by ELISA assays. Elisa results are presented as absolute values of pg per ml chemokine 
ligand per mg total protein in CRC and CRA tissues and unaffected neighbor tissues, respectively. The data are expressed as 
mean +/- standard error of the mean (SEM), * P < 0.05, ** P < 0.001, n = 48 and 30, respectively.BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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tion and tube formation in vitro. Moreover, the authors
observed that PGE2 promoted tumor growth in vivo by
induction of CXCL1 expression resulting in increased
tumor microvessel formation. In murine models of squa-
mous cell carcinoma and Lewis lung cancer CXCL1
expression was shown to parallel tumor growth [28,39]
and in adrenocortical and prostate carcinoma [40,41] as
well as in melanoma [29,42,43] CXCL1 was shown to
mediate tumorigenicity. Evidence supporting a role for
CXCL1 in CRC pathology was recently provided by a
study demonstrating an association between increased
expression of CXCL1 and down-regulation of the matrix
protein fibulin-1, which is known to suppress the motility
of various cancer cells [32]. Accordingly, Li et al [31]
investigated CXCL1 expression in human colon carci-
noma cells with different metastatic potentials and dem-
onstrated that constitutive expression of CXCL1 was
associated with metastatic potential and modulation of
colon cancer cell proliferation [31].
In line with these findings we also observed significant
up-regulation of CXCL1 in neoplastic colorectal tissues.
Moreover, we found significantly elevated CXCL1 expres-
sion in the CRA tissues of our patient cohort. However,
both chemokines CXCL1 and CXCL5 were shown to be
significantly higher expressed in the CRC tissues in com-
parison to the CRA tissues. Since CRA constitutes a prema-
lignant condition often preceding the development of
colorectal malignancies, we hypothesized that a signifi-
Detection of CXCL5 protein expression in representative  CRA, CRC and CRLM specimens as assessed by immunohis- tochemical staining with CXCL5 -specific antibodies Figure 7
Detection of CXCL5 protein expression in represent-
ative CRA, CRC and CRLM specimens as assessed by 
immunohistochemical staining with CXCL5 -specific 
antibodies. (A) Weak cytoplasmic signals in basal crypt cells 
within tumor neighbor tissues of CRA, (B) very weak immu-
nostaining in CRA specimens, (C) weak insular epithelial sig-
nals in tumor neighbor tissues of CRC, (D) intense basal and 
apical epithelial signals and interspersed rare mesenchymal 
signals in CRC tissues, (E) no substantial reactivity in corre-
sponding neighbour tissues of CRLM and (F) intensive stain-
ing signals in epithelial and mesenchymal cells within tumor 
areas of CRLM specimens (original magnification 200 and 400 
fold, respectively).
Detection of CXCL1 protein expression in representative  CRA, CRC and CRLM specimens as assessed by immunohis- tochemical staining with CXCL1 -specific antibodies Figure 6
Detection of CXCL1 protein expression in represent-
ative CRA, CRC and CRLM specimens as assessed by 
immunohistochemical staining with CXCL1 -specific 
antibodies. (A) Weak immunostaining in apical epithelial 
cells within tumor neighbor tissues of CRA, (B) weak to 
medium staining intensities in apical epithelial cells within 
CRA specimens, (C) weak insular signals in apical epithelial 
cells and goblet cells within tumor neighbor tissues of CRC, 
(D) intense ubiquitous epithelial signals and insular mesen-
chymal signals in CRC tissues, (E) medium staining intensities 
of fine granular texture in hepatocytes and (F) intense cyto-
plasmic signals in ubiquitous distribution in CRLM (original 
magnification 200 and 400 fold, respectively).BMC Cancer 2008, 8:178 http://www.biomedcentral.com/1471-2407/8/178
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cant increase of chemokine expression in the CRC tissues
with respect to the CRA tissues may indicate a transition
from the premalignant condition to the development of
the malignancy. This conclusion is supported by previous
studies showing elevated GROa expression in the intesti-
nal mucosa of patients with ulcerative colitis and Crohn's
disease which are known risk factors for the development
of CRC [44,45]. Although the basic expression level of
CXCL1 was generally higher in both disease entities in
comparison to CXCL5, we detected that CXCL5 overex-
pression was significantly more pronounced compared to
CXCL1. Moreover, we observed a significant clinicopatho-
logical association between CXCL5 expression and early
tumor categories of CRC which matched the expression
status of the corresponding primary tumors of the CRLM
in our investigation.
Conclusion
In our study, we outlined a prominent expression profile
for both chemokines, CXCL1 and CXCL5 with respect to
CRC pathology. On the basis of the current literature
CXCL1 appears to have a role in CRC related malignan-
cies. However, CXCL5 exhibited a much more pro-
nounced significant overexpression in the CRC and CRLM
tissues with respect to the CRA tissues thus indicating a
vast progressive increase in the transition from the prema-
lignant condition to the development of the malignant
status and thus, in the initiation of CRC. Since our results
are based merely on descriptive expression data, future
functional tests will be needed for further evaluation of
the precise pathophysiological role. However, the CXCL1
and CXCL5 expression profiles outlined in this study
strongly recommend monitoring the CXCL1 and CXCL5
expression in patients with CRA and CRC. Thus, we sug-
gest that targeting CXCL1 and CXCL5 signaling may be a
useful future tool in CRC pathology.
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